Endocyte Inc (ECYT)

NASDAQ
23.990
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    23.990/24.390
  • Day's Range:
    23.990 - 24.000

ECYT Overview

Prev. Close
24
Day's Range
23.99-24
Revenue
130K
Open
23.99
52 wk Range
0-0
EPS
-0.68
Volume
0
Market Cap
1.97B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
498,414
P/E Ratio
-
Beta
0.11
1-Year Change
0%
Shares Outstanding
82,097,630
Next Earnings Date
-
What is your sentiment on Endocyte Inc?
or
Market is currently closed. Voting is open during market hours.

Endocyte Inc News

Endocyte Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsSellSellStrong BuyStrong BuyStrong Buy
SummaryStrong SellSellStrong BuyStrong BuyStrong Buy

Endocyte Inc Company Profile

Endocyte Inc Company Profile

Employees
44

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company’s products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana. As of December 21, 2018, Endocyte, Inc. operates as a subsidiary of Novartis AG.

Read More
  • Holy Moly anyone know why the massive rally?
    0
    • they are being bought out by a company
      0
    • Novartis buying for $2.1 Billion
      0
  • Why no one posts here any more?
    0
    • It is going to be a red day.
      1
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.